TRC 253Alternative Names: JNJ 63576253; TRC253
Latest Information Update: 03 Mar 2017
At a glance
- Originator Janssen Pharmaceutica
- Class Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer